BPC-157 vs TB-500 comes down to two different research peptides with thin human evidence. BPC-157 comes from a gastric protein. TB-500 relates to thymosin beta-4. Here is how they compare, and how telos rx offers them.
Written by the telos rx Editorial Team. Last reviewed: 18 November 2026.
BPC-157 and TB-500 are often named in the same breath. Online, they are sold as recovery peptides and even pre-mixed into one vial. The science behind them is much less settled than the marketing suggests.
This comparison covers where each peptide comes from, what animal and human studies show, the safety unknowns and the US regulatory picture. Every section separates human evidence from animal and cell work.
BPC-157 vs TB-500 at a glance
| Feature | BPC-157 | TB-500 |
|---|---|---|
| What it is | A 15 amino acid synthetic peptide based on a protein found in gastric juice | A synthetic peptide related to thymosin beta-4, a protein found in many cells |
| Main research focus | Tendon, ligament, muscle and gut models in rodents | Cell movement, blood vessel growth and tissue repair models |
| Human evidence | Three small uncontrolled studies, 30 people in total | No published controlled human trials of TB-500 itself that we found |
| Animal evidence | Large volume, mostly rodents | Smaller volume, mostly rodents and cells |
| FDA status | Not FDA-approved | Not FDA-approved |
| HHS policy routes | Subcutaneous, intramuscular, oral, topical | Subcutaneous or intramuscular |
| Sport testing | Prohibited under WADA S0 | Prohibited under WADA S0 |
What is BPC-157?
BPC-157 stands for body protection compound 157. It is a lab-made chain of 15 amino acids, based on part of a protein in human gastric juice.
Animal and cell evidence: most BPC-157 research is in rats and mice. A 2025 systematic review in HSS Journal included 36 studies, and 35 of them were preclinical. Those studies looked at tendon, ligament, muscle and bone injury models.
Human evidence: a 2026 systematic review found only three human studies, with 30 people in total. All were rated poor quality, and the certainty of evidence was very low. Our guide to what BPC-157 is covers this in more depth.
What is TB-500?
TB-500 is a synthetic peptide linked to thymosin beta-4. Thymosin beta-4 is a natural protein that helps cells build their internal scaffolding and move.
Sources disagree on exactly what TB-500 contains. It is usually described as a short fragment based on one active region of thymosin beta-4. That matters, because research on the full protein does not automatically apply to the fragment.
Animal and cell evidence: most TB-500 and thymosin beta-4 research is in cells and animals. It looks at wound healing, blood vessel growth and tissue repair.
Human evidence: full-length thymosin beta-4 has entered small human studies, such as a trial in venous leg ulcers. We found no published controlled human trials of TB-500 itself.
TB-500 vs thymosin beta-4: why the difference matters
Many websites describe TB-500 and thymosin beta-4 as the same thing. They are not. One is a full natural protein. The other is a lab-made fragment.
When a seller cites thymosin beta-4 research to promote TB-500, read it carefully. The fragment may not behave like the whole protein in the body.
What studies compared them directly?
Very few. One 2026 rat study of Achilles tendon repair tested BPC-157, TB-500 and the two together against a control group, with eight rats per group.
Animal evidence only: both peptides were linked with better tissue scores at four weeks. TB-500 also showed a strength advantage. The combination did not add any benefit over either peptide alone.
The authors called it an exploratory study. It was small, in rats and given by injection into the abdomen. It cannot tell you what happens in people.
Considering BPC-157 or TB-500?
telos rx offers BPC-157 and TB-500 only as two separate single-ingredient vials after an online clinical review. BPC-157 and TB-500 are not FDA-approved, and any prescription is subject to medical approval by a licensed provider.
Learn about the two-vial optionMechanisms: what researchers think each one does
These ideas come from cell and animal work. They are hypotheses, not confirmed effects in people.
- BPC-157: lab studies suggest effects on growth hormone receptor expression, blood vessel growth and inflammatory signals.
- TB-500: lab studies focus on how thymosin beta-4 binds actin, a protein that helps cells change shape and move.
- Overlap: both are studied for blood vessel growth. The rat study above suggested they may act on shared pathways.
Safety unknowns for both peptides
A 2026 narrative review in Sports Medicine looked at peptides used in sports medicine, from licensed drugs to gray-market compounds. It found that many gray-market peptides look favourable in animal models, but rigorous human safety data are scarce.
- Long-term effects: not studied in people for either peptide.
- Blood vessel growth: both are studied for this effect. Researchers have asked whether that matters for people with cancer or a history of cancer. There is no human data.
- Pregnancy and breastfeeding: no human safety data.
- Product quality: products sold online for research use may be mislabelled or contaminated.
- Placebo effects: the same review discusses the placebo effect and how social media can amplify it.
Contact your clinician about injection-site redness that spreads, fever or any new symptom. Seek urgent care for swelling of the face or throat, or trouble breathing.
BPC-157 vs TB-500 and standard care
People usually compare these peptides because of an injury or joint pain. Standard care has far stronger evidence for those problems.
That includes a medical evaluation, imaging when needed, physical therapy, graded loading, sleep and good nutrition. Neither peptide replaces any of these. Our review of recovery peptide research sets the peptides beside standard options.
US status: the HHS enforcement discretion policy
On 30 October 2026, HHS published an interim enforcement discretion policy in the Federal Register, document 2026-22192. It covers six peptides, including BPC-157 and TB-500.
HHS said it will not take enforcement action against state-licensed pharmacies and physicians compounding these peptides until each is addressed in a final rule. Conditions include:
- A single active ingredient in each compounded product, so no blends.
- A valid, patient-specific prescription.
- Ingredients from FDA-registered suppliers.
- Set routes: BPC-157 subcutaneous, intramuscular, oral or topical. TB-500 subcutaneous or intramuscular.
This is not FDA approval. It is not a final listing, and HHS can revise it. Our HHS peptide policy explainer covers every condition. This summary reflects the policy as checked on 18 November 2026.
Can you use BPC-157 and TB-500 together?
Many sellers offer a single blended vial of both. Under the HHS policy, each compounded product must contain only one active ingredient. A pre-mixed blend falls outside the policy.
A provider may prescribe each peptide as its own single-ingredient product. Whether that makes sense for you is a clinical decision. Keep in mind that the one rat study testing both found no added benefit from combining them.
What about athletes?
BPC-157 and TB-500 are both prohibited in tested sport under category S0, non-approved substances, on the WADA Prohibited List. If you compete in tested sport, check the current list before using either.
How telos rx offers BPC-157 and TB-500
telos rx is an online-first, asynchronous telehealth service. You complete a private intake online, on your schedule. A licensed provider reviews it, and you can message your care team with questions.
TB-500 is not sold on its own. telos rx offers it only with BPC-157, as two separate single-ingredient vials, never one blend. The provider determines the dose and schedule for each vial, and medication ships ready to inject.
The BPC-157 and TB-500 page lists the two-vial option as low as $133 per month, as of 18 November 2026. BPC-157 is also offered on its own on the BPC-157 page. You can read about costs in our TB-500 cost guide.
The bottom line
BPC-157 and TB-500 are different molecules with mostly animal evidence. Neither has solid human trial data, and both are not FDA-approved. A licensed provider can weigh the unknowns, your history and standard care options before deciding whether either fits.
Start a private peptide evaluation
Answer health questions online, on your schedule. A licensed provider reviews them, and any prescription is subject to medical approval by a licensed provider.
Check my eligibilityFrequently Asked Questions
What is the main difference between BPC-157 and TB-500?
They are different molecules. BPC-157 is a 15 amino acid peptide based on a protein in gastric juice. TB-500 is a synthetic peptide related to thymosin beta-4, a protein involved in cell movement. Both have mostly animal research behind them, and both are not FDA-approved for any use in people.
Is BPC-157 or TB-500 better for injuries?
No one knows. There are no head-to-head human trials. One small rat study of Achilles tendon repair found both linked with better tissue scores, with TB-500 showing a strength advantage. Rat findings do not tell you what happens in people. Standard care such as physical therapy has stronger evidence.
Can BPC-157 and TB-500 be compounded in one vial?
Under the October 2026 HHS interim policy, each compounded product must contain a single active ingredient, so a blended vial falls outside it. A provider may prescribe each as a separate single-ingredient product. telos rx offers them only as two separate vials, never one blend.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a full natural protein. TB-500 is a lab-made peptide usually described as a fragment based on one region of it. Research on the full protein, including small human studies, does not automatically apply to TB-500. We found no controlled human trials of TB-500 itself.
Are BPC-157 and TB-500 legal?
Both are not FDA-approved. HHS published an interim enforcement discretion policy on 30 October 2026 covering compounding of both under strict conditions, including a patient-specific prescription and a single active ingredient. It is not approval or a final rule and can be revised. Check the current policy before relying on it.
Can athletes use BPC-157 or TB-500?
Both are prohibited under category S0, non-approved substances, on the WADA Prohibited List. If you compete in a tested sport, check the current list and your sport's rules before using either peptide. A prescription does not change their status in anti-doping testing.
telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.
Ready to see if it fits? Start your private evaluation with telos rx.